Changing the world

Quell Therapeutics (Quell) has announced $156 million in oversubscribed Series B financing to advance its pioneering multi-modular engineered T Regulatory (Treg) cell therapy pipeline and platform. The financing round was co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC with participation from founding investor Syncona. New investors

Apollo Therapeutics started life as an innovative fund, bringing together six powerhouses of UK academia and pharma to bridge the gap between promising life sciences discoveries and commercial medicines delivering patient benefit. Five years on, they are accelerating growth as an independent biotech company, developing a portfolio of programmes in oncology, inflammatory disorders and rare diseases into the clinic with a mission to create transformative new treatments.